NEOPHOTONICS CORPORA

NPTN
Delayed Quote. Delayed  - 01/22 04:10:00 pm
12.24USD -0.81%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2019 2020
Net sales1 357370
EBITDA1 32,751,1
Operating profit (EBIT)1 4,3522,1
Operating Margin 1,22%5,96%
Pre-Tax Profit (EBT)1 -15,4-3,05
Net income1 -17,1-3,60
Net margin -4,79%-0,97%
EPS2 -0,360,04
Dividend per Share --
Last update 02/27/2020-
1 USD in Million
2 USD
Estimates
Finances - Leverage
Fiscal Period: December 2019 2020
Net Debt1 --
Net Cash position1 -71,5
Leverage (Debt / EBITDA) --1,40x
Free Cash Flow1 25,238,5
ROE (Net Profit / Equities) -8,92%
Shareholders' equity1 --40,4
ROA (Net Profit / Asset) -4,49%
Assets1 --80,2
Book Value Per Share2 3,303,45
Cash Flow per Share --
Capex1 9,5315,5
Capex / Sales 2,67%4,19%
Last update 02/27/202011/03/2020
1 USD in Million
2 USD
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2020e 2021e
Capitalization 614 M $ -
Entreprise Value (EV) 542 M $ 534 M $
Valuation 2020e 2021e
P/E ratio (Price / EPS) 282x -31,7x
Capitalization / Revenue 1,66x 2,00x
EV / Revenue 1,46x 1,77x
EV / EBITDA 10,6x 19,2x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 3,54x 3,69x
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) 5,96% -2,91%
Operating Leverage (Delta EBIT / Delta Sales) x -8,17x
Net Margin (Net Profit / Revenue) -0,97% -7,94%
ROA (Net Profit / Asset) 4,49% -2,21%
ROE (Net Profit / Equities) 8,92% -4,32%
Rate of Dividend - -
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   4,19% 4,53%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) -0,22x 3,60x
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
EPS & Dividend